HFA Icon

Opioid Litigation Threatens Industry’s Survival

HFA Padded
Rupert Hargreaves
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Will the opioid crisis be similar to the tobacco one of the 1990s? Or even worse…?

In April 1994, the top executives of seven tobacco companies testified to a congressional hearing under oath that they didn’t believe nicotine was addictive. Over the next few years a flood of reports, studies and leaked internal documents emerged, revealing the opposite. Despite the testimony of the executive, it was widely known in the tobacco industry that nicotine was addictive at the time.

Three years later in 1997, the then-chief executives of Philip Morris and RJR Nabisco Holdings Corp (Reynolds American) met with attorneys to begin settlement talks for the industry’s mounting legal woes. States were demanding billions in compensation for treating smoking-related illnesses and also wanted funding...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha